Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
09/2005
09/22/2005US20050208563 Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof
09/22/2005US20050208562 Guanosine triphosphatase protein for use as tool in diagnosis and treatment of cell proliferative disorders
09/22/2005US20050208559 directed toward modulating oxidative damage to intracellular components such as mitochondrial DNA (mtDNA) and mitochondrial protein; antibody, or fragment thereof, that specifically binds to enzyme
09/22/2005US20050208552 Corpuscles of Stannius protein, stanniocalcin
09/22/2005US20050208546 Nucleotide sequences coding tumor associated antigens for use as tool in diagnosis, prevention and treatment of cell proliferative disorders
09/22/2005US20050208536 Comprises ribonuclease barnase marker gene; libraries; drug resistance
09/22/2005US20050208533 Modulators of morphogen expression and methods of identifying the same
09/22/2005US20050208527 Using neuregulin 1 derivatives as therapeutic agents in treatment of psychological disorders
09/22/2005US20050208525 Nucleotide sequences coding preferential polypeptide for use in the treatment defects in immune and inflammatory response
09/22/2005US20050208524 Full-length expressed genetic marker (FLEXGEM) polypeptide for use as diagnostic indicator of cell proliferative disorders
09/22/2005US20050208522 Fibroblast growth factor-like molecules and uses thereof
09/22/2005US20050208521 Modulation signal transduction; isolated nucleic acids; genetic engineering
09/22/2005US20050208514 Novel fibroblast growth factor and nucleic acids encoding dame
09/22/2005US20050208498 Killer cell immunoglobulin-like receptor (KIR)-like protein receptor for use in diagnosis, prevention and treatment of cancer, autoimmune disease, organ transplant rejection, allergic reaction, and inflammatory disorders
09/22/2005US20050208496 Using enhanced interleukin gene expression as diagnostic indicator of respiratory system disorders
09/22/2005US20050208492 Regulation of human serine/threonine kinase
09/22/2005US20050208488 Methods and materials relating to novel von willerband/thrombospondin-like polypeptides and polynucleotides
09/22/2005US20050208485 Pt32 sperm protein, sperm c-yes, oocyte cytoplasmic c-yes and uses thereof
09/22/2005US20050208484 Isolated nucleic acid molecules encoding human drugmetobolizing proteins
09/22/2005US20050208483 Kits for detecting anti-sirs antibodies
09/22/2005US20050208482 Tat-based immunomodulatory compositions and methods for their discovery and use
09/22/2005US20050208480 aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies
09/22/2005US20050208161 touchi plant extract and phaseolamin mixture for limiting the absorption of carbohydrates contained in a foodstuff, for promoting weight loss in an individual; nutraceuticals
09/22/2005US20050208151 Treatment of rheumatoid arthritis with FLIP antagonists
09/22/2005US20050208150 Compositions for elastrogenesis and connective tissue treatment
09/22/2005US20050208142 Production of nanoparticles having a defined number of ligands
09/22/2005US20050208138 Injection of a biocompatible polymer, polysaccharide or polyamino acid, a cross-linker, and therapeutic agent into tumor; hydrogel formed in the tumor retains the therapeutic agent; drug delivery method; sustained releasing the biodrug
09/22/2005US20050208137 comprising angiogenesis inhibitor retinoic acid, taxol and polymeric carrier polylactone; treating cancer, angiogenic-dependent diseases, embolizing blood vessels, and eliminating biliary, urethral, esophageal, tracheal/bronchial obstructions, corneal neovascularization; coated stents with the mixture
09/22/2005US20050208128 Immediate release tablet
09/22/2005US20050208126 Chemical ifg-i composition for the treatment and prevention of neurodgenerative diseases
09/22/2005US20050208121 Polymeric cannulae proteins, nucleic acids encoding them and methods for making and using them
09/22/2005US20050208114 Composition and method for healing tissues
09/22/2005US20050208103 Contacting sclera with a therapeutic or diagnostic agent so as to permit its passage into the choroidal and retinal tissues; no significant systemic absorption or tissue damage; eye disorders
09/22/2005US20050208095 Implanting a medical device by infiltrating a tissue of a host near the implant with an antifibrotic agent, and/or an antiinfective agent and/or a polymer; prevention of surgical adhesions
09/22/2005US20050208090 Implantable catheter system; treatment of inborn genetic errors or other defects that cause deficiencies of active enzymes or proteins within the cells of the central nervous system
09/22/2005US20050208079 Glucan-based vaccines
09/22/2005US20050208076 Combined with recombinant human serum albumin
09/22/2005US20050208075 Methods of using botulinum toxin for the treatment of hypervolemic lip deformity (lip ectropion)
09/22/2005US20050208069 Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
09/22/2005US20050208064 Peptide capable of inducing immune response to human gastric cancer and agent for preventing or treating human gastric cancer, containing the peptide
09/22/2005US20050208062 Compositions and methods relating to hepatic specific genes and proteins
09/22/2005US20050208061 Treatment of autoimmune diseases by oral administration of autoantigens
09/22/2005US20050208059 121P1F1: a tissue specific protein highly expressed in various cancers
09/22/2005US20050208053 Administering very late antigen-4, antigen binding fragment thereof, soluble vascular cell adhesion molecule-1 polypeptide; chimera
09/22/2005US20050208052 Screening for agonists/antagonists of interleukins; influenza virus; RNA interference; kits
09/22/2005US20050208051 Administering an antagonistic antibody immunoreactive with IL-1 epsilon for therapy of inflammatory and/or autoimmune disease selected from the group consisting of asthma, inflammatory bowel disease, psoriasis, and combinations thereof
09/22/2005US20050208050 Compounds for the diagnosis/prevention/treatment of alzheimer's disease
09/22/2005US20050208049 Expanding CD4 + T cells; antiretroviral drug; induce active pathogen replication in cell latently infected with HIV and anti-pathogen drug
09/22/2005US20050208046 TWEAK receptor
09/22/2005US20050208042 Inducing lack of responsiveness to an antigen in an individual having a transplanted organ, tissue, cell; administering an effective amount of a humanized antibody; one antigen binding region of nonhuman origin and a portion of an immunoglobulin heavy chain of human origin
09/22/2005US20050208040 Polynucleotides and polypeptides encoded thereby
09/22/2005US20050208039 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
09/22/2005US20050208038 Isolated polypeptide is amino acid sequence; lytic enzyme comprises a first isolated amino acid sequence homolog; In vitro Killing Assay; In vivo Nasal Infection Assay
09/22/2005US20050208037 Chemotherapeutic agent anthracycline is doxorubicin, daunomycin; radiotherapeutic agent; adenoviral vector; administered intravenously, intramuscularly, intralesionally, subcutaneously, by aerosol
09/22/2005US20050208036 Graft versus host disease; administering lymphocytes ,hematopoietic stem cells
09/22/2005US20050208035 Nutritional composition for treating an immune condition
09/22/2005US20050208028 Nutrient Medium for maintaining neural cells in injured nervous system
09/22/2005US20050208027 Methods and compositions for regeneration of aged tissues
09/22/2005US20050208019 Uses of interferons with altered spatial structure
09/22/2005US20050208017 Immuno-modulating effects of chemokines in DNA vaccination
09/22/2005US20050208016 derivatives effectively block the inflammatory effects of RANTES, and are useful for the treatment of asthma, allergic rhinitis, atopic dermatitis, atheroma/atherosclerosis, and rheumatoid arthritis, hiv
09/22/2005US20050208014 In situ formation of a polymeric cyanoacrylate film containing mixed antibiotics applied as a liquid or gel to the skin surface
09/22/2005US20050208011 Hair follicle growth
09/22/2005US20050208000 Compositions and methods for prevention of photoaging
09/22/2005US20050207995 Methods and compositions for promoting oral health, and polypeptides useful for same
09/22/2005US20050207988 Polysaccharides for pulmonary delivery of active agents
09/22/2005US20050207975 administering monoclonal Tac-antibodies; anticarcinogenic agents; immunotherapy
09/22/2005US20050206023 formation of particles of a target substance, such as a pharmaceutical, using a supercritical or near-critical fluid as an anti-solvent
09/22/2005DE102004011988A1 Cyclosporinderivate und diese enthaltende pharmazeutische Zusammensetzungen Cyclosporin derivatives and pharmaceutical compositions containing them
09/22/2005CA2787978A1 Interferon-beta for anti-virus therapy for respiratory diseases
09/22/2005CA2564614A1 Combinatorial interleukin-2 muteins
09/22/2005CA2559887A1 Method for inhibiting immune complex formation in a subject
09/22/2005CA2559172A1 Therapeutic use of rm1 antigen
09/22/2005CA2559167A1 Modified annexin proteins and methods for preventing thrombosis
09/22/2005CA2559124A1 Novel phosphorylated sequences of phosphatase cdc25b, antibodies directed against said sequences and use thereof
09/22/2005CA2559062A1 Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
09/22/2005CA2559060A1 Phospholipases, nucleic acids encoding them and methods for making and using them
09/22/2005CA2558984A1 Recombinant chondroitinase abc i and uses thereof
09/22/2005CA2558976A1 Mvl, an antiviral protein from a cyanobacterium
09/22/2005CA2558803A1 Pharmaceutical compositions comprising interferon-tau
09/22/2005CA2558771A1 Multiple promoter expression cassettes for simultaneous delivery of rnai agents
09/22/2005CA2558645A1 Method of optimizing treatment with interferon-tau
09/22/2005CA2558632A1 Improved interleukin-2 muteins
09/22/2005CA2558050A1 Methods and compositions for the treatment of gastrointestinal disorders
09/22/2005CA2558039A1 Treating or preventing extracellular matrix build-up
09/22/2005CA2558025A1 Cell-penetrating socs polypeptides that inhibit cytokine-induced signaling
09/22/2005CA2557307A1 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
09/22/2005CA2557249A1 Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
09/22/2005CA2557247A1 Compounds as inhibitors of hepatitis c virus ns3 serine protease
09/22/2005CA2555908A1 Use of corticotroph-derived glycoprotein hormone to treat liver steatosis
09/22/2005CA2555792A1 Therapeutic administration of the scrambled anti-angiogenic peptide c16y
09/22/2005CA2555541A1 Cd38 splice variant and uses thereof
09/21/2005EP1577391A1 Neutrokine alpha
09/21/2005EP1577383A1 Novel adaptor protein binding to mammalian toll-like receptor 3 and gene thereof
09/21/2005EP1577382A2 Detection of TSE infectivity
09/21/2005EP1577323A1 Metastin derivative and use thereof
09/21/2005EP1577322A1 Novel proteins and use thereof
09/21/2005EP1577321A1 Hydrophobically-modified protein compositions and methods
09/21/2005EP1577320A1 Peptides derived from human BPLP protein, polynucleotides coding for said peptides and antibodies directed against said peptides
09/21/2005EP1576978A2 Device for administering insulin in controlled dosages by controlling total inhaled volume
1 ... 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 ... 3163